WO2009060915A1 - Salivary secretion promoter - Google Patents

Salivary secretion promoter Download PDF

Info

Publication number
WO2009060915A1
WO2009060915A1 PCT/JP2008/070238 JP2008070238W WO2009060915A1 WO 2009060915 A1 WO2009060915 A1 WO 2009060915A1 JP 2008070238 W JP2008070238 W JP 2008070238W WO 2009060915 A1 WO2009060915 A1 WO 2009060915A1
Authority
WO
WIPO (PCT)
Prior art keywords
salivary secretion
secretion promoter
bbi
active ingredient
promoter
Prior art date
Application number
PCT/JP2008/070238
Other languages
French (fr)
Japanese (ja)
Inventor
Takeshi Sakamoto
Akira Katsushima
Atsushi Yokomizo
Takashi Matsuda
Toshiaki Fujitani
Original Assignee
San-Ei Gen F.F.I., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by San-Ei Gen F.F.I., Inc. filed Critical San-Ei Gen F.F.I., Inc.
Priority to JP2009540088A priority Critical patent/JP5634066B2/en
Publication of WO2009060915A1 publication Critical patent/WO2009060915A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Abstract

Disclosed is a salivary secretion promoter, particularly a salivary secretion promoter having a form suitable for the administration or ingestion through an oral route or a form suitable for use in an oral cavity, such as a composition for oral administration and an intraoral composition. The salivary secretion promoter is characterized by comprising a Bowman-Birk protease inhibitor (BBI) as an active ingredient. The salivary secretion promoter may further comprise potassium, in addition to the BBI. The salivary secretion promoter may comprise a plant extract containing a BBI as an active ingredient.
PCT/JP2008/070238 2007-11-06 2008-11-06 Salivary secretion promoter WO2009060915A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009540088A JP5634066B2 (en) 2007-11-06 2008-11-06 Salivary secretion promoter

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007288974 2007-11-06
JP2007-288974 2007-11-06

Publications (1)

Publication Number Publication Date
WO2009060915A1 true WO2009060915A1 (en) 2009-05-14

Family

ID=40625802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/070238 WO2009060915A1 (en) 2007-11-06 2008-11-06 Salivary secretion promoter

Country Status (2)

Country Link
JP (1) JP5634066B2 (en)
WO (1) WO2009060915A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012044918A (en) * 2010-08-26 2012-03-08 Japan Health Science Foundation Packaged beverage
JP2016063832A (en) * 2016-01-26 2016-04-28 公益財団法人ヒューマンサイエンス振興財団 Packed beverage
WO2017094910A1 (en) 2015-12-04 2017-06-08 三栄源エフ・エフ・アイ株式会社 Use of enzyme-modified isoquercitrin

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6351335A (en) * 1986-08-20 1988-03-04 Fuji Oil Co Ltd Degranulation inhibitor for mast cell
JP2001081011A (en) * 1999-07-27 2001-03-27 Johnson & Johnson Consumer Co Inc Method for treating pigmentation in skin
JP2002539093A (en) * 1999-03-12 2002-11-19 ジョージタウン ユニバーシティ Matriptase, serine protease and its application
JP2005500331A (en) * 2001-07-18 2005-01-06 ソラ，エルエルシー High protein Bowman-Birk inhibitor-concentrate and process for its production
JP2005529899A (en) * 2002-05-01 2005-10-06 ケミン・コンシューマー・ケアー・エル・シー Composition or method for reducing blood glucose after a meal
WO2005107780A2 (en) * 2004-05-10 2005-11-17 Instituto Tecnológico Y De Estudios Superiores De Monterrey (Itesm) Cancer cell growth inhibition by black bean (phaseolus vulgarisl) extracts

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6351335A (en) * 1986-08-20 1988-03-04 Fuji Oil Co Ltd Degranulation inhibitor for mast cell
JP2002539093A (en) * 1999-03-12 2002-11-19 ジョージタウン ユニバーシティ Matriptase, serine protease and its application
JP2001081011A (en) * 1999-07-27 2001-03-27 Johnson & Johnson Consumer Co Inc Method for treating pigmentation in skin
JP2005500331A (en) * 2001-07-18 2005-01-06 ソラ，エルエルシー High protein Bowman-Birk inhibitor-concentrate and process for its production
JP2005529899A (en) * 2002-05-01 2005-10-06 ケミン・コンシューマー・ケアー・エル・シー Composition or method for reducing blood glucose after a meal
WO2005107780A2 (en) * 2004-05-10 2005-11-17 Instituto Tecnológico Y De Estudios Superiores De Monterrey (Itesm) Cancer cell growth inhibition by black bean (phaseolus vulgarisl) extracts

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012044918A (en) * 2010-08-26 2012-03-08 Japan Health Science Foundation Packaged beverage
WO2017094910A1 (en) 2015-12-04 2017-06-08 三栄源エフ・エフ・アイ株式会社 Use of enzyme-modified isoquercitrin
JP2016063832A (en) * 2016-01-26 2016-04-28 公益財団法人ヒューマンサイエンス振興財団 Packed beverage

Also Published As

Publication number Publication date
JPWO2009060915A1 (en) 2011-03-24
JP5634066B2 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
WO2007109812A3 (en) Immunopotentiating compounds
RS51569B (en) Compositions comprising crystalline trans-(+/-)-delta-9-tetrahydrocannabinol
WO2006031878A3 (en) Imidazoquinoline compounds
WO2009105568A1 (en) Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
MY146247A (en) Solid pharmaceutical dosage form comprising ritonavir
WO2005025541A3 (en) Dry powder composition comprising a benzodiazepine for pulmonary inhalation
WO2006096614A3 (en) Angiogenic heparin binding peptide amphiphiles
HK1126934A1 (en) Glycerol levulinate ketals and their use
WO2009100441A3 (en) Depot formulations
MY148412A (en) Oral compositions containing oxidized camellia
WO2008025819A3 (en) Formulations of acetylsalicylic acid or its derivatives in soft capsules, exhibiting high stability
WO2004078105A3 (en) Fondaparinux sodium composition of high purity, method for production of said composition and pharmaceutical compositions containing the same as active ingredient
HRP20090511T1 (en) Compositions for vaginal use
WO2007030361A3 (en) Benzimidazole thiophene compounds as plk inhibitors
WO2008052033A3 (en) Ibuprofen composition
MX2009010989A (en) Lyophilized pharmaceutical compositions and methods of making and using same.
WO2007132134A3 (en) Compositions comprising at least one naphthoic acid derivative and benzoyl peroxide, methods for preparing same, and uses thereof
WO2008157304A3 (en) Stabilized thrombin compositions
WO2008106979A3 (en) Pharmaceutical compositions comprising flavonoids and xylitol
EP2011544A3 (en) Structured Depilatory Compositions
WO2012009438A3 (en) Anti-appetite adhesive compositions
WO2009060915A1 (en) Salivary secretion promoter
WO2005051083A3 (en) Molluscicidal and anti-barnacle compounds
WO2004112771A8 (en) Pharmaceutical compositions including an antihistamine and a stimulant and use thereof
MXPA05008403A (en) Use of edible acid in fast-dispersing pharmaceutical solid dosage forms.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08848084

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009540088

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08848084

Country of ref document: EP

Kind code of ref document: A1